Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making—A Narrative Review
Aliya Nurmukhanbetova, Kassymkhan Sultanbekov, Khussan Umurzakov, Zie Gassanov, Altyn Duisenbayeva, Alimkhan Talas, Lazzat Shaikenova, Aidos Bolatov · 2026
Read Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making—A Narrative Review by Aliya Nurmukhanbetova, Kassymkhan Sultanbekov, Khussan Umurzakov, Zie Gassanov, Altyn Duisenbayeva, Alimkhan Talas, Lazzat Shaikenova, Aidos Bolatov (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565365.txt.
Description
Aliya Nurmukhanbetova and seven co-authors review urine tests for cancers of the urinary system in a 2026 paper. Urine is easy to collect repeatedly, yet urine biomarkers are rarely used in clinics. The authors argue that a marker's worth depends on the decision at hand, how the signal reaches urine, and when and how the sample is taken.
They survey markers across bladder, upper urinary tract, prostate, and kidney cancers: tumor DNA, chemical gene tags, proteins, immune signals, vesicles, metabolites, and microbe traces. Bladder cancer is the most mature case, with uses from blood-in-urine workups to recurrence watching. Prostate tests fit biopsy decisions best. Kidney markers lag furthest behind. The review is a decision-first map of the field.
Catalog record
| CREATOR | Aliya Nurmukhanbetova, Kassymkhan Sultanbekov, Khussan Umurzakov, Zie Gassanov, Altyn Duisenbayeva, Alimkhan Talas, Lazzat Shaikenova, Aidos Bolatov |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 109 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |